Biogen Inc (BIIB)
NASDAQ · Healthcare · Drug Manufacturers - General
Biogen Inc is a Healthcare company with a market capitalization of $31.89B and a trailing P/E ratio of 23.3.
5-Year Price History
Latest Annual Financials · FY ending December 31, 2025
Recent Quarterly Earnings (EPS)
| Quarter | Reported | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| Q1 2026 | April 29, 2026 | $3.57 | $2.89 | +23.5% |
| Q4 2025 | February 6, 2026 | $1.99 | $1.62 | +22.8% |
| Q3 2025 | October 30, 2025 | $4.81 | $3.88 | +24.0% |
| Q2 2025 | July 31, 2025 | $5.47 | $3.88 | +41.0% |
| Q1 2025 | May 1, 2025 | $3.02 | $2.95 | +2.4% |
| Q4 2024 | February 12, 2025 | $3.44 | $3.36 | +2.4% |
Other Drug Manufacturers - General Stocks
Frequently Asked Questions
What is Biogen Inc's market cap?
As of June 29, 2026, Biogen Inc (BIIB) has a market capitalization of $31.89B.
What is Biogen Inc's P/E ratio?
Biogen Inc trades at a trailing price-to-earnings (P/E) ratio of 23.3. Its forward P/E is 14.5.
Does Biogen Inc pay a dividend?
Biogen Inc does not currently pay a dividend.
What sector is BIIB in?
Biogen Inc is in the Healthcare sector, specifically the Drug Manufacturers - General industry.
What was Biogen Inc's revenue?
In its latest reported fiscal year (ending December 31, 2025), Biogen Inc reported revenue of $9.81B and net income of $1.29B.
Ask your own questions about BIIB
Try mrmarket.ai freeData as of June 29, 2026. Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.